In addition, GM-CSF treatment improved Treg functionality, implying that immunological modulation with GM-CSF enhanced Treg-mediated immune regulation, which is considerably reduced in PD patients, suggesting an effective therapeutic option. This evidence concerns the gene CSF2 and Parkinson disease.